Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 823-829, February 15, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guo, W.-X.
Right arrow Articles by Antakly, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guo, W.-X.
Right arrow Articles by Antakly, T.

Inhibition of AIDS-Kaposi's Sarcoma Cell Proliferation following Retinoic Acid Receptor Activation1

Wei-Xing Guo, Parkash S. Gill and Tony Antakly2

Department of Pathology, University of Montreal, C. P. 6128, Succursale, Centreville, Montreal, Quebec, Canada H3C 3J7 [W-X. G., T. A.], and Norris Cancer Center, University of Southern California, Los Angeles, California 90033 [P. S. G.]

Retinoids, a group of natural and synthetic vitamin A analogues the receptors of which belong to the superfamily of steroid receptors, can exert profound effects on growth and/or differentiation of embryonic and neoplastic cells. Kaposi's sarcoma (KS), previously a rare multicentric neoplasm, has become epidemic with HIV infection, although the etiology of KS remains obscure. In the present study, the effects of two potent retinoids, all-trans-retinoic acid (RA) and 13-cis-RA, on the expression of retinoic acid receptor {alpha} and the growth of AIDS-related KS (AIDS-KS) cells were examined. The proliferation of AIDS-KS cells was significantly inhibited by RA and 13-cis-RA in a dose-dependent manner with 50% inhibitory concentration of 1.4 x 10-10 M and 4.7 x 10-9 M, respectively, which correlate with their potency. Growth inhibition was time dependent with maximal inhibition of 90% after 3 days of treatment with 10-8 M RA. Growth inhibition by RA was further potentiated by forskolin (1 µM), an intracellular cyclic AMP-inducing agent. Moreover, RA treatment blocked the proliferative effect of oncostatin M and tumor necrosis factor {alpha}, two major KS autocrine growth factors. The effects of RA were accompanied by a dramatic increase in nuclear staining for retinoic acid receptor {alpha} and in the relative number of strongly positive retinoic acid receptor {alpha} nuclei. Finally, RA induced morphological changes as KS cells became more flattened, better spread, and more adhesive to the substrate. These results suggest that retinoids inhibit proliferation of AIDS-KS cells and further support their utility as therapeutic agents in AIDS-KS.

1 This work was supported by National Cancer Institute of Canada Grant 2196 and in part by Medical Research Council of Canada Grant MA 7959. W-X. G. is currently a recipient of a National Health Ph.D. Fellowship from Health Canada and an earlier Ph.D. studentship from the Fonds pour la formation de Chercheurs et l'Aide à la Recherche, Quebec, Canada.

2 To whom requests for reprints should be addressed.

Received 8/ 9/94. Accepted 12/16/94.




This article has been cited by other articles:


Home page
Arch DermatolHome page
D. M. Aboulafia, D. Norris, D. Henry, R. J. Grossman, J. Thommes, D. Bundow, R. C. Yocum, and V. Stevens
9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma: Results of a Phase 2 Multicenter Clinical Trial
Arch Dermatol, February 1, 2003; 139(2): 178 - 186.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
M. Duvic, A. E. Friedman-Kien, D. J. Looney, S. A. Miles, P. L. Myskowski, D. T. Scadden, J. Von Roenn, J. E. Galpin, J. Groopman, G. Loewen, et al.
Topical Treatment of Cutaneous Lesions of Acquired Immunodeficiency Syndrome-Related Kaposi Sarcoma Using Alitretinoin Gel: Results of Phase 1 and 2 Trials
Arch Dermatol, December 1, 2000; 136(12): 1461 - 1469.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
K. Antman and Y. Chang
Kaposi's Sarcoma
N. Engl. J. Med., April 6, 2000; 342(14): 1027 - 1038.
[Full Text] [PDF]


Home page
BloodHome page
H. Asou, J. W. Said, R. Yang, R. Munker, D. J. Park, N. Kamada, and H. P. Koeffler
Mechanisms of Growth Control of Kaposi's Sarcoma-Associated Herpes Virus-Associated Primary Effusion Lymphoma Cells
Blood, April 1, 1998; 91(7): 2475 - 2481.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Cai, T. Zheng, M. Lotz, Y. Zhang, R. Masood, and P. Gill
Glucocorticoids Induce Kaposi's Sarcoma Cell Proliferation Through the Regulation of Transforming Growth Factor-beta
Blood, March 1, 1997; 89(5): 1491 - 1500.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.